|Articles|September 1, 1997

The Treatment of Hypercholesterolemia: A Managed Care Perspective
Volume 3
Issue 8 Suppl

Managing Comorbidities through Cholesterol-Lowering

Author(s)Alan O. Marcus, MD

Download PDF: Managing Comorbidities through Cholesterol-Lowering

Articles in this issue

almost 29 years ago

Article

Goals and Objectives

almost 29 years ago

Article

Introduction

almost 29 years ago

Article

The Rationale for Treating Hypercholesterolemia

almost 29 years ago

Article

Lowering Risk Factors through Cholesterol Treatment: Overview of the Recent Major Trials

almost 29 years ago

Article

Preventing Coronary Heart Disease in the Managed Care Era: Improving the Cost Effectiveness of Lipid-Lowering Therapy with HMG-CoA Reductase Inhibitors

almost 29 years ago

Article

Treating Hyperlipidemia to Prevent Coronary Heart Disease: What Are the Treatment Goals and How Do We Get There?

almost 29 years ago

Article

CME Quiz

almost 29 years ago

Article

Selected Abstracts

almost 29 years ago

Article

Bibliography

almost 29 years ago

Article

Participants

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Managing Comorbidities through Cholesterol-Lowering

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies